Literature DB >> 31413023

Time-to-effect of fluoxetine in children with depression.

Tyler Yan, Ran D Goldman.   

Abstract

Question I prescribed fluoxetine to a 16-year-old female patient presenting to my clinic with severe major depressive disorder who did not respond to psychotherapy. Is fluoxetine an effective treatment of depression in this population, and how long should she expect to wait before noticing an effect?Answer For depression in children and adolescents, fluoxetine has the most evidence for efficacy when compared with other selective serotonin reuptake inhibitors; however, it is not approved by Health Canada for this patient population. Available evidence has shown that most of its clinical benefit is seen within the first 2 weeks. Lack of response by week 4 might suggest a need for reevaluation. However, more research is needed to elucidate the optimal length of the initial treatment period. There is conflicting evidence regarding the risk of suicidality in this population, so close patient monitoring is required when using fluoxetine in children and adolescents. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31413023      PMCID: PMC6693597     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  25 in total

1.  Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; John Davis; J John Mann
Journal:  Arch Gen Psychiatry       Date:  2012-06

2.  SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-02

3.  When should a trial of fluoxetine for major depression be declared failed?

Authors:  Frederic M Quitkin; Eva Petkova; Patrick J McGrath; Bonnie Taylor; Charles Beasley; Jonathan Stewart; Jay Amsterdam; Maurizio Fava; Jerrold Rosenbaum; Frederick Reimherr; Jan Fawcett; Ying Chen; Donald Klein
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

4.  Investigating health correlates of adolescent depression in Canada.

Authors:  Tracie O Afifi; Murray W Enns; Brian J Cox; Patricia J Martens
Journal:  Can J Public Health       Date:  2005 Nov-Dec

5.  Timing of onset of antidepressant response with fluoxetine treatment.

Authors:  A A Nierenberg; A H Farabaugh; J E Alpert; J Gordon; J J Worthington; J F Rosenbaum; M Fava
Journal:  Am J Psychiatry       Date:  2000-09       Impact factor: 18.112

Review 6.  Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.

Authors:  Matthew J Taylor; Nick Freemantle; John R Geddes; Zubin Bhagwagar
Journal:  Arch Gen Psychiatry       Date:  2006-11

Review 7.  Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.

Authors:  Corrado Barbui; Eleonora Esposito; Andrea Cipriani
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

8.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

9.  Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.

Authors:  Graham J Emslie; John H Heiligenstein; Karen Dineen Wagner; Sharon L Hoog; Daniel E Ernest; Eileen Brown; Mary Nilsson; Jennie G Jacobson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-10       Impact factor: 8.829

10.  Depression in adolescence.

Authors:  Anita Thapar; Stephan Collishaw; Daniel S Pine; Ajay K Thapar
Journal:  Lancet       Date:  2012-02-02       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.